HCLTech Delivers Robust Performance in Q2FY26 with Revenue Growth of 4.6%
13.10.2025 20:08:00 CEST | Business Wire | Press Release
HCLTech, a leading global technology company, reported 4.6% YOY revenue growth in constant currency (CC) for the quarter ended September 30, 2025. USD revenue was at $3.6 billion, up 5.8% YoY. The company revised its Services Revenue growth (CC) guidance to 4%-5%, while retaining the overall revenue and margin guidance for FY26.
“We had a standout quarter on every front — marked by strong execution, growing demand for our AI-powered solutions and Advanced AI revenue exceeding $100 million this quarter. Our AI strategy is no longer just a vision; it is now a measurable driver of growth, differentiation and innovation. We are transitioning into an AI monetization phase. For the first time, our new bookings surpassed $2.5 billion, without reliance on any mega deal,” said C Vijayakumar, CEO & Managing Director, HCLTech.
HCLTech’s Services revenue grew by 5.5% YoY (CC). Digital revenue was up 15% YoY (CC) and now accounts for 42% of Services revenue. HCLSoftware’s Annual Recurring Revenue, at $1.06 billion, continues to grow.
Industry vertical growth was led by Technology and Services at 13.9% YoY growth (CC), followed by Telecommunications, Media, Publishing and Entertainment at 11.7% YoY (CC) and Financial Services at 11.4% YoY (CC). In terms of geographies, Europe grew at 7.6% YoY (CC) while the Rest of the World grew the fastest at 17.9% YoY (CC). The U.S. grew by 2.4%.
The company announced a dividend of ₹12 per share for the quarter, marking the 91st consecutive quarter of dividend payouts.
“HCLTech delivered strong INR revenue growth of 5.2% QoQ and 10.7% YoY in Q2 FY26. This superior revenue growth is accompanied by enhanced profitability and solid cash generation, with the last twelve months (LTM) FCF/NI ratio at 125%. We remain committed to improving our capital efficiency and are pleased to report LTM ROIC for the company is 38.6%, up 290 bps YoY and for Services business is 45.3%, up 180 bps YoY,” added Shiv Walia, Chief Financial Officer, HCLTech.
The company added 5,196 freshers during the quarter, taking the H1 fresher addition to 7,180. The LTM attrition moderated to 12.6%, among the lowest in the industry.
Key deal wins:
- A leading US-based vacation ownership and resort management company expanded its partnership with HCLTech to modernize and transform its finance, accounting and mortgage operations with AI-powered digital solutions.
- A US-based global consumer goods major selected HCLTech as its strategic partner to manage a large portfolio of enterprise applications and infrastructure across commercial, supply chain and corporate functions.
- A Europe-based global retail major selected HCLTech to modernize its multi-channel application landscape. HCLTech’s solution will leverage AI Force to deliver a digital-first, future-ready platform that will enable seamless customer experiences across online and in-store channels.
Key AI deal wins:
- A UK-based financial services major selected HCLTech to modernize its digital banking platforms and boost productivity. The solution uses AI Force to automate and augment the software development lifecycle, enabling faster time-to-market, improved platform resilience and superior digital experiences for its users.
- A public sector transport authority in Australia selected HCLTech to enhance safety and compliance across waterways using a computer vision-based Physical AI solution. Built on HCLTech AI Foundry, the solution enables real-time detection of congestion, unsafe behavior and hazards at boat ramps, reducing response times and preventing accidents.
- A US-based global manufacturer selected HCLTech AI Advisory services to build an Enterprise AI and Governance framework to scale AI initiatives with measurable ROI, regulatory compliance and Responsible AI principles.
- A leading US-based telecom company selected HCLTech to launch an NVIDIA-powered Emerging Tech AI Lab. HCLTech is delivering advanced Cognitive Infrastructure Services, setting up a high-performance AI cluster and deploying state-of-the-art models such as Llama 405B, Maverick and Scout. This scalable, future-ready platform enables rapid AI experimentation and enterprise-wide AI adoption, reducing time-to-market and driving transformation.
HCLTech received dual recognition from TIME magazine: Highest-ranked India-headquartered technology company for the second consecutive year in the World’s Best Companies 2025 list and ranked among the top 15 in Professional Services in the World’s Most Sustainable Companies 2025 list.
About HCLTech
HCLTech is a global technology company, home to more than 226,600 people across 60 countries, delivering industry-leading capabilities centered around AI, digital, engineering, cloud and software, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG, Mobility and Public Services. Consolidated revenues as of 12 months ending September 2025 totaled $14.2 billion. To learn how we can supercharge progress for you, visit hcltech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013228975/en/
Contacts
For further details, please contact:
Meredith Bucaro, Americas
meredith-bucaro@hcltech.com
Elka Ghudial, EMEA
elka.ghudial@hcltech.com
James Galvin, APAC
james.galvin@hcltech.com
Nitin Shukla, India
nitin-shukla@hcltech.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom